Targeting Fibroblast-Derived Interleukin 6: A Strategy to Overcome Epithelial-Mesenchymal Transition and Radioresistance in Head and Neck Cancer
Cancers · 15.01.2025 · 17 (2) · 267
DOI: 10.3390/cancers17020267 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 15.01.2025. Verfasst von Xinyang Li und 3 weiteren Autor:innen. Beteiligte Einrichtung: Head and Neck Oncology Group, Centre for Host Microbiome Interaction, King's College London, Hodgkin Building, London SE1 1UL, UK. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: King's College London, Joint PhD program between King’s College London and China Scholarship Council, Luxembourg National Research Fund.
Abstract (Originalsprache)
Background
Cancer-associated fibroblasts have been reported to play a central role in driving cancer progression, promoting metastasis, and conferring resistance to therapy in HNSCC.
Methods
Indirect and direct co-culture models of HPV-positive and HPV-negative HNSCC cells with fibroblasts were developed to study the effect of fibroblasts on cancer cells. ELISA was used to measure IL-6 secretion in these models. To dissect the underlying signalling mechanisms, the effects of IL-6, an IL-6 receptor (IL-6R) inhibitor, a MAPK/ERK inhibitor, and a JAK/STAT inhibitor were evaluated. Epithelial-to-mesenchymal transition (EMT) was assessed by measuring EMT markers and conducting scratch assays and spheroid assays. Radioresistance was evaluated using clonogenic assays. Additionally, radioresistant (RR) cell lines were established from parental cells to examine the correlation between radioresistance and EMT.
Results
Fibroblasts were found to drive EMT-like changes and heightened radioresistance in HNSCC cells through IL-6 secretion. Remarkably, these Fb-driven effects were robustly reversed using IL-6R and MAPK/ERK inhibitors in both HPV-positive and HPV-negative cell lines, whereas JAK/STAT inhibitors proved effective only in HPV-negative cells. RR cell lines exhibit a more aggressive phenotype than their parental counterparts, marked by pronounced EMT features and heightened resistance to radiotherapy. Importantly, these aggressive characteristics were substantially attenuated by targeting IL-6R or MAPK/ERK pathways.
Conclusions
This study highlights the critical role of fibroblast-secreted IL-6 in driving and maintaining EMT and radioresistance in HNSCC, resulting in a more aggressive tumour phenotype. Targeting the IL-6/IL-6R/ERK pathway emerges as a promising therapeutic approach for combating CAF-driven tumour progression and improving clinical outcomes in patients with aggressive, therapy-resistant HNSCC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Head and Neck Oncology Group, Centre for Host Microbiome Interaction, King's College London, Hodgkin Building, London SE1 1UL, UK.
- Department of Life Sciences and Medicine, University of Luxembourg, L-4370 Belvaux, Luxembourg.
ORCID-Profile: Hugues Escoffier, Thomas Sauter, Mahvash Tavassoli
Förderung
- King's College London
- Joint PhD program between King’s College London and China Scholarship Council
- Luxembourg National Research Fund
Zitieren
APA
Li, X., Escoffier, H., Sauter, T., & Tavassoli, M. (2025). Targeting Fibroblast-Derived Interleukin 6: A Strategy to Overcome Epithelial-Mesenchymal Transition and Radioresistance in Head and Neck Cancer. Cancers, 17(2), 267. https://doi.org/10.3390/cancers17020267
Vancouver
Li X, Escoffier H, Sauter T, Tavassoli M. Targeting Fibroblast-Derived Interleukin 6: A Strategy to Overcome Epithelial-Mesenchymal Transition and Radioresistance in Head and Neck Cancer. Cancers. 2025;17(2):267. doi:10.3390/cancers17020267
BibTeX
@article{Li2025,
author = {Li, Xinyang and Escoffier, Hugues and Sauter, Thomas and Tavassoli, Mahvash},
title = {Targeting Fibroblast-Derived Interleukin 6: A Strategy to Overcome Epithelial-Mesenchymal Transition and Radioresistance in Head and Neck Cancer},
journal = {Cancers},
year = {2025},
volume = {17},
number = {2},
pages = {267},
doi = {10.3390/cancers17020267}
}
EUVIMED